Kymera Therapeutics Q1 2024 net loss $48.6M; cash $745M; pipeline progresses

Kymera Therapeutics, Inc.

2024-Q1 EPS reported -$0.69 revenue$10,287,000

Net loss $48.6M in Q1 2024 vs $40.9M in Q1 2023; collaboration revenue $10.3M.
Cash, cash equivalents and investments $745M as of March 31, 2024.
Cash runway extended into first half of 2027 following $301M equity offering.
KT-474 IRAK4 degrader Phase 2 trials in HS and AD ongoing; topline data H1 2025.
KT-621 STAT6 degrader Phase 1 start H2 2024; KT-294 TYK2 degrader Phase 1 start H1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 2, 2024, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-051566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.